This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.2 | Special Copayment Reduction: V117 | Special Copayment Reduction period: 5 years |
| B. Synonyms | MLD, metachromatic leukodystrophy, ARSA Deficiency, Sulfatidosis |
| C. Adult onset | Moderate likelihood of first presentation in adulthood — adult-onset MLD accounts for about 20–25% of all patients and often begins with psychiatric symptoms. |
| 1. History | Described by Alzheimer and Greenfield in 1910; arylsulfatase A deficiency confirmed in 1959; ARSA gene cloned |
| 2. Causes | ARSA gene mutations → arylsulfatase A deficiency → sulfatide accumulation in the central and peripheral nervous systems |
| 3. Genetics | Autosomal recessive, ARSA (22q13.33), more than 200 variants, type I (severe)/type A (mild) alleles |
| 4. Epidemiology | 1 per 40,000–160,000 births; the late infantile form is the most common |
| 5. Pathophysiology | Lysosomal sulfatide accumulation → death of oligodendrocytes and Schwann cells → progressive demyelination |
| 6. Symptoms | Late infantile form: motor regression → spasticity; juvenile form: behavioral and cognitive decline; adult form: psychiatric symptoms → neurodegeneration |
| 7. Signs | MRI tiger-stripe white matter lesions, reduced nerve conduction on NCS, increased urinary sulfatides |
| 8. Screening | DBS ARSA enzyme activity measurement, measurement of plasma/urine sulfatides and lyso-sulfatide |
| 9. Diagnosis | Reduced ARSA enzyme activity + pathogenic ARSA gene variants + increased urinary sulfatides |
| 10. Treatment | Lenmeldy (atidarsagene autotemcel) gene therapy approved in 2024; presymptomatic HSCT is effective |
| 11. Prognosis | Early gene therapy or HSCT can preserve neurodevelopment; treatment after symptom onset has limited effect |
| 12. Prevention | Genetic counseling, carrier testing, PGT, presymptomatic early detection through newborn screening |
| 13. References | Austin JH. Metachromatic form of diffuse cerebral sclerosis and 9 other papers |
The history of metachromatic leukodystrophy (MLD) dates back to the early 20th century. In 1910, Alois Alzheimer described a progressive neurodegenerative disease with white matter degeneration, and in 1933 Greenfield recorded the characteristic pathologic finding of metachromatic material deposited in brain and peripheral nerve tissue. The name "metachromatic" derives from the fact that, when stained with cresyl violet or toluidine blue, this material shows a different hue, brown to brownish red rather than blue.
In 1959, Austin found that arylsulfatase A (ARSA) activity was markedly reduced in brain tissue from patients with MLD, establishing MLD as a lipid storage disease caused by lysosomal sulfatase deficiency. In the 1960s, sulfatide (3-O-sulfogalactosylceramide) was confirmed to be the identity of the metachromatic material and the key accumulating substrate of MLD. With advances in molecular biology techniques in the 1980s, the ARSA gene was cloned and various pathogenic variants were discovered.
In the 2000s, it was clinically confirmed that hematopoietic stem cell transplantation (HSCT) can suppress the progression of neurodegeneration in presymptomatic patients. In 2013, Aiuti et al. in Milan, Italy, first reported that ARSA gene therapy using a lentiviral vector was safe and effective in patients with MLD, and this study became a landmark turning point in the field of gene therapy for rare genetic diseases. After evidence accumulated through subsequent clinical studies, the US FDA approved atidarsagene autotemcel (brand name Lenmeldy) in 2024 as a gene therapy for MLD.
Most MLD (about 95%) is caused by functional deficiency of the lysosomal enzyme arylsulfatase A (ARSA) due to ARSA gene mutations. Within the lysosome, ARSA catalyzes the hydrolysis of sulfatide (galactocerebroside-3-sulfate), a major sphingolipid, to galactocerebroside. When ARSA activity is deficient, sulfatide and its degradation product lyso-sulfatide progressively accumulate in the myelin-forming cells of the central and peripheral nervous systems (oligodendrocytes, Schwann cells), neurons, renal tubular cells and others.
Rarely (about 5%), MLD is also caused by deficiency of saposin B (encoded by the prosaposin gene PSAP), a cofactor protein essential for binding of sulfatide to ARSA. In this case the ARSA enzyme itself is expressed normally but cannot function, and ARSA enzyme activity measurement is normal, which can cause diagnostic confusion. Therefore, when MLD is strongly suspected clinically despite normal ARSA enzyme activity, PSAP gene analysis is needed to check for saposin B deficiency. Sulfatide and lyso-sulfatide exert strong cytotoxicity, and their accumulation is the key cause of demyelination and degeneration of the nervous system.
MLD is inherited in an autosomal recessive manner. The causative gene ARSA is located at chromosome 22q13.33 and consists of 8 exons. More than 200 pathogenic ARSA variants have been reported to date. An important concept in the genetics of MLD is the distinction between "allele I" and "allele A." Type I alleles include variants that completely abolish enzyme activity (e.g., p.Pro426Leu) and are associated with severe early-onset phenotypes. Type A alleles include variants that markedly reduce but do not completely abolish enzyme activity.
According to genotype-phenotype correlations, I/I homozygosity (0% enzyme activity) tends to be associated with the late infantile or juvenile form, I/A compound heterozygosity with the juvenile or adult form, and A/A compound heterozygosity with the adult form. However, because clinical phenotypes vary even with the same genotype, it is difficult to predict the clinical course of an individual patient accurately from genotype alone. The ARSA pseudodeficiency allele is present in the general population at a frequency of about 1–2%; in this case enzyme activity is low but there are no clinical symptoms, so caution is needed because false positives can occur when diagnosis is based on ARSA enzyme activity alone.
The incidence of MLD is estimated at about 1 per 40,000–160,000 births, which is relatively high among lysosomal storage diseases. It occurs worldwide and is not limited to any particular race, but high frequencies have been reported in some populations. High frequencies due to a founder effect have been reported in the Jewish Habbanite community in Israel, Navajo Indians, Romani communities in Europe, and parts of Pakistan and the Middle East.
By clinical form, the late infantile form accounts for about 50–60% of all patients with MLD, the juvenile form about 20–30% and the adult form about 15–25%. Adult-onset MLD is often misdiagnosed as a psychiatric disorder such as schizophrenia or manic disorder, so its actual prevalence may be underestimated. In Korea, a small number of cases have been reported, and it is included in the national lysosomal storage disease registry. There is no difference in incidence between males and females.
The pathophysiology of MLD begins with progressive accumulation of sulfatide and lyso-sulfatide in the central and peripheral nervous systems due to ARSA deficiency. Sulfatide is a major lipid component of myelin and is normally continuously produced and degraded during myelin turnover. In ARSA deficiency, sulfatide cannot be degraded in lysosomes and accumulates in oligodendrocytes, Schwann cells and some neurons. Sulfatide accumulation activates apoptotic pathways in these cells, promoting cell death.
Lyso-sulfatide, the lyso form of sulfatide, is more strongly neurotoxic and has been reported to cause mitochondrial dysfunction, endoplasmic reticulum stress and neuroinflammatory responses. Death of oligodendrocytes causes impaired myelination and demyelination in the central nervous system, reducing nerve conduction, and death of Schwann cells causes demyelination in the peripheral nervous system, producing peripheral neuropathy. Pathologically, accumulation of metachromatic material (sulfatide) in the cerebral white matter, showing brown-red metachromasia with cresyl violet, is characteristic, and sulfatide accumulation is also observed in renal tubular cells. This cellular damage leads to demyelination throughout the nervous system, resulting in widespread neurologic decline.
MLD is classified into three main clinical forms according to age at onset. Late infantile MLD begins at 12–24 months of age and is the most common and most severe. Initial symptoms are gait instability, hypotonia and frequent falls, followed by progression of language regression, dysphagia, seizures, generalized spasticity and optic atrophy. Within a few years it leads to complete quadriplegia and a decreased level of consciousness.
Juvenile MLD begins between 4 and 16 years of age, with declining school performance, behavioral changes and cognitive regression as initial symptoms. Neurologic symptoms such as gait disturbance, spasticity, seizures and visual decline are then added. Adult MLD begins after age 16 and shows very diverse clinical presentations. It initially presents with psychiatric symptoms (personality change, memory decline, depression, psychosis, bizarre behavior) and is often misdiagnosed as schizophrenia or a mood disorder. After months to years, neurologic symptoms (spastic paralysis, ataxia, peripheral neuropathy) are gradually added, progressing to dementia, quadriplegia and so on. The adult form progresses much more slowly than the infantile form.
On neurologic examination, decreased or absent deep tendon reflexes (reflecting peripheral nervous system demyelination) and mild hypotonia are observed initially. As the disease progresses, limb spasticity, pathologic reflexes (Babinski sign) and visual decline due to optic atrophy are found. Ataxia due to cerebellar dysfunction may also be present.
The characteristic brain MRI finding in MLD is confluent T2 hyperintense lesions in the white matter of both cerebral hemispheres, starting in the periventricular white matter and progressing to the subcortical white matter. In particular, the corpus callosum, internal capsule and occipital white matter are involved early. Radial striped T2 hypointense bands in the periventricular white matter, called the "tiger stripe pattern," are reported as a characteristic MRI finding in MLD. Nerve conduction studies (NCS) show reduced motor and sensory nerve conduction velocities, confirming peripheral nervous system demyelination. Quantitative urine sulfatide analysis (LC-MS/MS) shows a marked increase, and plasma lyso-sulfatide is also increased. These biomarkers are also used to monitor treatment response.
Newborn screening for MLD is currently being introduced on a pilot basis in some countries. Screening methods include measurement of ARSA enzyme activity in dried blood spots (DBS) and measurement of sulfatide and lyso-sulfatide concentrations in urine or plasma by mass spectrometry. Measurement of ARSA enzyme activity alone makes it difficult to differentiate ARSA pseudodeficiency (present in about 1–2% of the general population, who are clinically normal but have low enzyme activity), so false positives can occur. Therefore, a multistep algorithm is recommended in which DBS ARSA enzyme activity measurement is performed as the primary screen and, if abnormal, urine/plasma lyso-sulfatide measurement and ARSA gene analysis are performed as secondary tests.
Plasma lyso-sulfatide concentration is specifically elevated in patients with MLD and is normal in ARSA pseudodeficiency, making it a very useful secondary biomarker for differentiating the two conditions. Inclusion of MLD in lysosomal storage disease newborn screening panels is currently being discussed in Europe and some US states, and with the approval of gene therapy (Lenmeldy), linking early screening to treatment has become even more important. Early detection through newborn screening is essential for presymptomatic treatment.
MLD is confirmed by integrating ① biochemical tests, ② molecular genetic tests and ③ clinical and imaging findings. Biochemical confirmation consists of confirming that ARSA enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts is reduced to less than 10% of normal and that urinary sulfatide excretion is markedly increased (above age-based reference). Molecular genetic confirmation is the identification of pathogenic variants on both alleles of the ARSA gene.
A point of caution in clinical diagnosis is that in ARSA pseudodeficiency, enzyme activity is low but sulfatide excretion is normal and there are no neurologic symptoms. Therefore, an increase in urinary sulfatide (or plasma lyso-sulfatide) must be confirmed biochemically to exclude pseudodeficiency. In addition, because ARSA enzyme activity is normal in MLD due to saposin B deficiency, PSAP gene testing is needed when MLD is strongly suspected clinically despite normal ARSA enzyme activity. The differential diagnosis includes MSD, Krabbe disease, Pelizaeus-Merzbacher disease, other leukodystrophies and mitochondrial diseases. On histopathology, metachromatic lipid deposits on nerve biopsy or kidney biopsy support the diagnosis.
A historic turning point in the treatment of MLD is the 2024 US FDA approval of atidarsagene autotemcel (brand name Lenmeldy). Lenmeldy is an autologous gene therapy in which the patient's own hematopoietic stem cells are corrected ex vivo with a functional ARSA gene using a lentiviral vector and then transplanted back. This treatment was approved for presymptomatic late infantile patients, early symptomatic late infantile patients and presymptomatic juvenile patients. Clinical studies confirmed that many patients treated before symptom onset maintained motor and cognitive function at normal or near-normal levels.
Before Lenmeldy, hematopoietic stem cell transplantation (HSCT) was the main treatment for MLD and is effective in suppressing the progression of neurodegeneration in presymptomatic juvenile or adult patients. Some effect of presymptomatic HSCT in the late infantile form has also been reported, but its effect is limited compared with gene therapy. Studies of direct intracerebral gene therapy using AAV vectors are also under way. Enzyme replacement therapy (ERT) has limited effectiveness because ARSA cannot cross the blood-brain barrier, but approaches via intrathecal or intracerebroventricular administration are being studied. A strategy of inhibiting sulfatide synthesis by substrate reduction therapy (SRT) is theoretically possible but has not yet reached the clinical stage. Supportive treatment includes anticonvulsants, physical therapy, nutritional support and pain management.
The prognosis of MLD varies greatly with clinical form and whether treatment is given. In the late infantile form, most patients die within 5–10 years of onset without treatment. In clinical trials of late infantile patients who received Lenmeldy gene therapy before symptom onset, more than about 80% were reported to maintain motor function and be able to walk independently for several years after treatment. In the juvenile form, presymptomatic HSCT or gene therapy is effective in maintaining neurologic function, but reversal of symptoms that have already appeared is difficult to expect.
Adult MLD follows a slowly progressive course over decades, and some patients survive 20–30 years or more. The effect of HSCT in adult patients differs between studies, with an effect on suppressing progression reported in some. Patients who do not receive gene therapy or HSCT eventually reach complete dependence. Functional status at treatment, brain MRI lesion burden and plasma lyso-sulfatide concentration are being studied as the main predictors of treatment response.
Because MLD is an autosomal recessive genetic disease, when both parents are heterozygous carriers of pathogenic ARSA variants, an affected child can be born with a 25% probability in each pregnancy. Carrier testing of parents and genetic counseling are essential, and couples who have already had an affected child should receive genetic counseling before the next pregnancy. Because of the existence of ARSA pseudodeficiency alleles, enzyme activity alone may be insufficient for carrier testing, so genetic testing is recommended.
Prenatal diagnosis is possible by ARSA enzyme activity measurement and ARSA gene analysis in samples obtained by CVS (10–12 weeks of gestation) or amniocentesis (16–18 weeks of gestation). Preimplantation genetic testing (PGT) is a method in which, in couples at high risk of MLD, embryos are screened for ARSA variants after in vitro fertilization and healthy embryos are transferred, and it can prevent the birth of an affected child. Diagnosing MLD before symptom onset through newborn screening and performing gene therapy early is currently the most effective strategy for improving outcomes, and for this, discussion on introducing a national screening program is needed.